StemRIM
4599.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.28B
Close$
$86.05
47.5% downside
Current Fair Value
47.5% downsideOvervalued by 47.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.28 Billion |
|---|---|
| Enterprise Value | $4.90 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-29.63 |
| Beta | 1.12 |
| Outstanding Shares | 62,213,000 |
Return
| Return on Equity | -32.41% |
|---|---|
| Return on Assets | -31.33% |
| Return on Invested Capital | -34.30% |
Valuation & Multiples
| P/E Ratio | -5.52 |
|---|---|
| PEG | 148.03 |
| Price to Sales | - |
| Price to Book Ratio | 1.8 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.45 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
December 16, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About StemRIM
45 employees
CEO: Masatsune Okajima StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is curre...